Sorbitol dehydrogenase inhibitors (SDIs): a new potent, enantiomeric SDI, 4-[2-1R-hydroxy-ethyl)-pyrimidin-4-yl]piperazine-1-sulfonic acid dimethylamide. | J Med Chem;44(17): 2695-700, 2001 Aug 16. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Sorbitol dehydrogenase inhibitors (SDIs): a new potent, enantiomeric SDI, 4-[2-1R-hydroxy-ethyl)-pyrimidin-4-yl]piperazine-1-sulfonic acid dimethylamide.

Mylari, B L; Oates, P J; Beebe, D A; Brackett, N S; Coutcher, J B; Dina, M S; Zembrowski, W J.

Affiliation

Mylari BL; Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research & Development, Pfizer Inc., Groton, Connecticut 06340, USA. lmylari@home.com

J Med Chem ; 44(17): 2695-700, 2001 Aug 16.

Article in En | MEDLINE | ID: mdl-11495581

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Enzyme Inhibitors / L-Iditol 2-Dehydrogenase Limits: Animals / Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2001 Document type: Article Affiliation country:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Enzyme Inhibitors / L-Iditol 2-Dehydrogenase Limits: Animals / Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2001 Document type: Article Affiliation country: